Laura Montiel‐Cervantes

Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis

Jaime Garcı́a-Chávez, Abraham Majluf‐Cruz, Laura Montiel‐Cervantes et al. · Annals of Hematology · 2007 · 64 citations · Full text

Immunology, Pharmacotherapy, Immunotherapy +17

Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor

Jorge Vela‐Ojeda, Maria Esparza, Y. Padilla-González et al. · Annals of Hematology · 2008 · 56 citations

Hematological Malignancy, Alzheimer's Disease, Multiple Myeloma-associated Amyloidosis +2

Low number of invariant NKT cells is associated with poor survival in acute myeloid leukemia

Alicia E. Najera Chuc, Laura Montiel‐Cervantes, Flor Pérez Retiguin et al. · Journal of Cancer Research and Clinical Oncology · 2012 · 48 citations · Full text

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Acute Myeloid Leukemia +9

Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia

Jorge Vela‐Ojeda, Miriam Esparza, Alejandro Rosas-Cabral et al. · Annals of Hematology · 2002 · 45 citations

Hematological Malignancy, Oncology, Medicine +8

Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia

Daniela Sandoval‐Borrego, Martha C. Moreno‐Lafont, Ernesto A. Vázquez-Sánchez et al. · Archives of Medical Research · 2016 · 43 citations

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +9